NDA 019734 · Chiesi
Cardene In 4.8% Dextrose In Plastic Container
Nicardipine Hydrochloride · Intravenous, Injection
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Jan 30, 1992
Approved uses
1
Original approval plus efficacy supplements
Registered trials
47
10 Phase 3, 4 recruiting
FAERS reports
2,241
2,186 serious, 296 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 13, 2026.
• CARDENE I.V. is a calcium channel blocker indicated for the short-term treatment of hypertension in adults when oral therapy is not feasible. ( 1.1 ) 1.1 Hypertension CARDENE I.V. (nicardipine hydrochloride) is indicated in adults for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits [see Dosage and Administration (2.1) ].
Mechanism: Nicardipine inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine are more selective to vascular smooth muscle than cardiac muscle. In animal models, nicardipine produced relaxation of coronary vascular smooth muscle at drug levels which cause little or no negative inotropic effect.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 30, 1992 Original approval · Type 3 - New Dosage Form
5 products under this application
- CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER · NICARDIPINE HYDROCHLORIDE 20MG/200ML (0.1MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
- CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER · NICARDIPINE HYDROCHLORIDE 40MG/200ML (0.2MG/ML) · INJECTABLE, INTRAVENOUS · Discontinued
- CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER · NICARDIPINE HYDROCHLORIDE 20MG/200ML (0.1MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP
- CARDENE · NICARDIPINE HYDROCHLORIDE 25MG/10ML (2.5MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER · NICARDIPINE HYDROCHLORIDE 40MG/200ML (0.2MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Nicardipine" as an intervention, any sponsor and status, largest first.
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- Nicardipine to Avoid Spasm in Trans Radial Percutaneous Coronary InterventionPivotal-lookingCompleted
Pr. Semir NouiraAcademic, hospital or other
NCT04538534 · 1,500 participants · Start Nov 1, 2020 · Primary completion Feb 1, 2022
Drug: Nicardipine · For: Spasm Artery
Sites: Monastir, Tunisia
- Antihypertensive Treatment of Acute Cerebral Hemorrhage-IIPivotal-lookingTerminated
University of MinnesotaAcademic, hospital or other
NCT01176565 · 1,000 participants · Start May 15, 2011 · Primary completion Dec 21, 2015
Drug: Intravenous nicardipine hydrochloride · For: Intracerebral Hemorrhage
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 171 sites in all
- Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093925 · 739 participants · Start May 2004 · Primary completion Jul 2006
Drug: clevidipine; nicardipine · For: Hypertension
Sites: Mobile, Alabama; Wichita, Kansas; New Orleans, Louisiana · 9 sites in all
- Intraarterial Nitroglycerin Versus Nicardipine and Radial Artery OcclusionPivotal-lookingCompleted
Hermina Heart Center KemayoranAcademic, hospital or other
NCT03622060 · 600 participants · Start Jun 4, 2018 · Primary completion May 21, 2019
Drug: Nitroglycerin · For: Radial Artery Injury at Wrist and Hand Level; Occlusion of Artery; Vasodilation
Sites: Jakarta Pusat, Indonesia
- Intensive Blood Pressure Reduction in Acute Cerebral HaemorrhagePivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT00226096 · 404 participants · Start Nov 2005 · Primary completion Sep 2007
Drug: Labetalol Hydrochloride; Metoprolol tartrate and 9 more · For: CVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial Hemorrhages
Sites: Concord, Australia; Gosford, Australia; Kogarah, Australia · 20 sites in all
- Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT TrialPivotal-lookingRecruiting
The Affiliated Hospital Of Guizhou Medical UniversityAcademic, hospital or other
NCT06329635 · 396 participants (planned) · Start May 27, 2024 · Primary completion May 2026
Drug: Intrathecal Nicardipine · For: Aneurysmal Subarachnoid Hemorrhage; Vasospasm
Sites: Hefei, China; Beijing, China; Chongqing, China · 28 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- acute kidney injury121
- hypotension98
- premature baby98
- off label use90
- maternal exposure during pregnancy87
- foetal exposure during pregnancy74
- pyrexia71
- diarrhoea68
- drug interaction66
- fall61
- hyponatraemia59
- confusional state58
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 15 |
| 2006 | 96 |
| 2007 | 96 |
| 2008 | 57 |
| 2009 | 74 |
| 2010 | 50 |
| 2011 | 46 |
| 2012 | 86 |
| 2013 | 28 |
| 2014 | 21 |
| 2015 | 39 |
| 2016 | 33 |
| 2017 | 62 |
| 2018 | 130 |
| 2019 | 89 |
| 2020 | 78 |
| 2021 | 120 |
| 2022 | 239 |
| 2023 | 224 |
| 2024 | 239 |
| 2025 | 261 |
| 2026 | 136 |
Recalls
1 FDA enforcement reports for this application.
Aug 6, 2026 · Class II · Ongoing
CGMP Deviations
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review.
Wang T, Jiang R, Yao Y, et al. · Hypertens Pregnancy 2024 · Systematic Review, Network Meta-Analysis
- Raynaud's phenomenon (primary).
Pope JE · BMJ Clin Evid 2011 · Systematic Review
- The effect of blood pressure lowering medications on the prevention of episodic migraine: A systematic review and meta-analysis.
Carcel C, Haghdoost F, Shen J, et al. · Cephalalgia 2023 · Meta-Analysis, Systematic Review
- Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials.
Dayyani M, Sadeghirad B, Grotta JC, et al. · Stroke 2022 · Systematic Review, Network Meta-Analysis
- Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review.
Ayub A, Zamir A, Imran I, et al. · Expert Opin Drug Metab Toxicol 2024 · Systematic Review
- Localized Nicardipine Release Implants for Prevention of Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Randomized Clinical Trial.
Wessels L, Wolf S, Adage T, et al. · JAMA Neurol 2024 · Randomized Controlled Trial, Multicenter Study
Sponsor: Chiesi · Also marketed as Cardene In 5.0% Dextrose In Plastic Container, Cardene In 0.86% Sodium Chloride In Plastic Container, Cardene, Cardene In 0.83% Sodium Chloride In Plastic Container
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.